The WHO and ICC differ slightly on their nomenclature and criteria for defining this condition; however, both acknowledge the presence of the hypercellularity of the bone marrow and predominance of erythroblast precursors, as well as a supporting TP53 mutation with evidence of biallelic inactivation [6,11]. Here, TP53 is linked to intrahepatic cholangiocarcinoma.